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ABSTRACT: Data were pooled from several studies on nicotinic acid (NiAc) intervention of fatty acid turnover in normal Sprague–Dawley
and obese Zucker rats in order to perform a joint PKPD of data from more than 100 normal Sprague–Dawley and obese Zucker rats,
exposed to several administration routes and rates. To describe the difference in pharmacodynamic parameters between obese and normal
rats, we modified a previously published nonlinear mixed effects model describing tolerance and oscillatory rebound effects of NiAc on
nonesterified fatty acids plasma concentrations. An important conclusion is that planning of experiments and dose scheduling cannot rely
on pilot studies on normal animals alone. The obese rats have a less-pronounced concentration–response relationship and need higher
doses to exhibit desired response. The relative level of fatty acid rebound after cessation of NiAc administration was also quantified in
the two rat populations. Building joint normal-disease models with scaling parameter(s) to characterize the “degree of disease” can be a
useful tool when designing informative experiments on diseased animals, particularly in the preclinical screen. Data were analyzed using
nonlinear mixed effects modeling, for the optimization, we used an improved method for calculating the gradient than the usually adopted
finite difference approximation. C© 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci
Keywords: pharmacodynamics; nonesterified fatty acids (NEFAs); nonlinear regression; diseasemodeling; feedback;mathematicalmodels;
monte carlo; disease state; sensitivity analysis
INTRODUCTION
Nicotinic acid (NiAc) is a lipid lowering agent that inhibits
lipolysis in adipose tissue by activating the GPR109A recep-
tor, resulting in a pronounced decrease in plasma nonesterified
fatty acids (NEFAs) concentrations.1 Current understanding
of the mechanism is that activation of the G protein-coupled
receptor GPR109A by NiAc inhibits adenylyl cyclase activity,
leading to decreased formation of cyclic adenosine monophos-
phate (cAMP) from adenosine triphosphate. cAMP regulates
lipolysis in adipocytes by activating protein kinase A that phos-
phorylates hormone-sensitive lipase (HSL). NiAc thus reduces
the hydrolysis of triglycerides (TG) into NEFAs and glycerol,
which is catalyzed by HSL.2 A feedback model describing NiAc-
induced changes in NEFA plasma concentrations has previ-
ously been published.3–5 The characteristics described by the
model are tolerance and oscillatory rebound effects, and de-
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pending on the parameter values, the model can be used for
either Sprague–Dawley rats or obese Zucker rats.
Obese Zucker rats display insulin resistance and obesity,
and are frequently used as a disease model. Obesity is fre-
quently associated with insulin resistance and known to in-
fluence the distribution and clearance of compounds.6–10 This
suggests that insulin resistance, in an animal or a patient,
can alter the pharmacokinetics (PK) and pharmacodynamics
(PD) of the NiAc/NEFA system with changes in onset, duration
and intensity of the drug effects. As a normal model, Sprague–
Dawley rats are used. Their lipoprotein and lipid patterns are
similar to those of the lean Zucker rat and therefore can serve
as a normal model for comparison purposes.11,12
Analyzing all data collected during a preclinical screen al-
lows us to better quantify the difference in PD between normal
Sprague–Dawley rats and obese Zucker rats. A full analysis
of all data available also allows us to better understand how
drug response in normal animals translates to the diseased
animals. This is particularly valuable for decisions made in
the preclinical phase, which are often based on selected data
from a normal animal model. We therefore sought to determine
how disease affects the PD and to quantify this effect. This re-
port describes such a joint analysis that utilized data from 95
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Sprague–Dawley rats and 19 obese Zucker rats simultaneously,
to estimate the relative change in pivotal parameters across
normal and diseased animals. Data were analyzed using non-
linear mixed effects modeling in which, for the optimization,
we used a more exact method for calculating the gradient than
the usually adopted finite difference approximation.13
We also compare our joint analysis to population PK/PD
analysis carried out separately for normal and obese rats to in-
vestigate which PD parameters are affected by the disease. The
combined analysis uses all available data simultaneously to
maximize the information content from which inference about
a pathophysiological system can bemade. In amore general set-
ting, this kind of modeling can be used to combine knowledge
gained from previous, less information-rich studies. Accumu-
lating information into models over the life-span of a discov-
ery project, can in this way reduce the number of future mea-
surements or studies but still keep the quantitative quality of
results.
MATERIALS AND METHODS
The following material is mainly adapted from previous
publications3–5 but is repeated here for the convenience of the
reader.
Chemicals
Nicotinic acid (pyridine-3-carboxylic acid) was obtained from
Sigma–Aldrich (St. Louis, Missouri) and was dissolved in 0.9%
NaCl. All solvents were of analytical grade and the water used
in the experiments was obtained from a water purification sys-
tem (Elgastat Maxima, ELGA, Lane End, UK).
Animals and Surgical Procedures
Male obese Zucker (fa/fa) and normal male Sprague–Dawley
rats were purchased fromHarlan Laboratories Nederlands B.V.
(Horst, the Netherlands) at 7 and 11 weeks of age, respectively,
and used at 16weeks of age. The animals were housed in groups
of 5–6 with free access to standard rodent chow (R3; Laktamin
AB, Stockholm, Sweden) and tap water. They were kept in
climate-controlled facilities at a room temperature of 20◦C–
22◦C and relative humidity of 40%–60% under a 12:12-h light–
dark cycle. The study was approved by the Ethics Committee
for Animal Experiments, Gothenburg, Sweden (EA 100868).
Surgery was performed under isoflurane (ForeneQR; Abbott
Scandinavia AB, Solna, Sweden) anesthesia and body temper-
ature was maintained at 37◦C using a thermoregulated heat-
ing pad. Catheters were implanted in the left carotid artery
for blood sampling and in the right external jugular vein for
drug administration, as previously described.14 Before cannu-
lation, catheters (IntramedicQR, PE50; Becton, Dickinson and
Company, Franklin Lakes, New Jersey) were filled with ster-
ile sodium-citrate solution (20.6 mM sodium-citrate in ster-
ile saline; Pharmaceutical and Analytical R&D, AstraZeneca,
Mo¨lndal, Sweden) to prevent clotting. After cannulation, the
catheters were exteriorized at the nape of the neck and sealed.
After surgery, the rats were housed individually and allowed
5 days to recover before the experiments began.
Experimental Design
The animals were fasted for 14 h before dosing and throughout
the experiment to minimize the fluctuations in NEFA caused
by food intake. They had free access to drinking water during
the length of fast. On the day of experimentation, they were
weighed, moved to clean cages, and the venous catheters were
connected to infusion pumps (CMA 100; Carnegie Medicin AB,
Stockholm, Sweden). Following a 30 min adaptation period,
two consecutive arterial blood samples were collected 15 and 5
min before drug administration to determine predose baseline
NEFA and NiAc concentrations. Normal Sprague–Dawley rats
(weighing 220–367 g) were assigned to 12 groups. Groups 1–8
received an intravenous constant rate infusion for either 30 or
300 min. Four of the eight groups received vehicle (0.9% NaCl,
n = 10), or 1 (n = 4), 5 (n = 8) or 20 (n = 9) :mol kg−1 NiAc
over 30 min. The remaining four groups received vehicle (n =
8), or 5 (n = 9), 10 (n = 8) or 51 (n = 7) :mol kg−1 NiAc over 300
min. Groups 9–12 received oral doses by gavage with vehicle
or 24.4, 81.2, or 812 :mol kg−1 NiAc (n = 6 per group). The
concentrations of the dosing solutions were adjusted to give
infusion volume flow rates in the range of 0.4–22 :L min−1 and
oral dosing volume in the range of 1.4–1.6 mL, based on body
weight. The dosing solutions were prepared within 30 min of
administration by dissolving an appropriate amount of NiAc in
saline solution. Among groups 9–12, two groups (n = 5 in each)
received a constant infusion of NiAc of 5 :mol kg−1 for 30 min,
followed by a stepwise decrease in infusion rate every 10 min.
The last of the two groups was given a 5 :mol kg−1 for 30min at
210 min. Control groups had the same schemes (n = 1 in each)
but received vehicle. Obese Zucker rats (weighing 473–547 g)
were assigned to four groups of which received an intravenous
constant rate infusion for either 30 or 300 min. Two groups
received vehicle (0.9% NaCl, n = 2) or 20 (n = 8) :mol kg−1
NiAc over 30 min. The other two groups received vehicle (n =
2) or 51 (n = 7) :mol kg−1 NiAc over 300 min.
Multiple arterial blood samples were drawn, 11–15 per rat,
for both the 30 and 300 min infusion experiments for analy-
sis of NiAc and NEFA plasma concentrations. The total blood
volume removed did not exceed 1.5 mL, and was replaced with
an equal volume of sterile sodium-citrate solution to maintain
a constant circulatory volume. The control rats received the
same volume of infusion solution (vehicle) as the NiAc groups,
and all animals were subjected to similar sampling procedures.
The blood samples (120 :L each) were collected in EDTA coated
polyethylene tubes and kept on ice until centrifuged (10,000g,
5 min, 4◦C). The plasma was stored at −20◦C pending analysis.
The start of infusion was taken as time zero (0 min).
Analytical Assays
Analysis and quantification of NiAc in plasma were performed
using liquid chromatography—mass spectrometry. The HPLC
system was an Agilent 1100 Series (Hewlett-Packard GmbH,
Walbronn, Germany) coupled to an HTC PAL autosampler
(CTC Analytics AG, Zwingen, Germany). Plasma samples (50
:L per sample) were precipitatedwith cold acetonitrile contain-
ing 0.2% formic acid (150 :L per sample). After vortex mixing
and centrifugation at 4◦C (4000g, 20 min), an aliquot of 100
:L of the supernatant was used for analysis. The mobile phase
consisted of (A) 2% acetonitrile and 0.2% formic acid in wa-
ter, and (B) 0.2% formic acid in acetonitrile. Separation was
performed on a 50 × 2.1 mm Biobasic AX column with 5 lm
particles (Thermo Hypersil-Keystone, Runcorn, Cheshire, UK)
with a gradient of 95%–20% B over 1 min, held at 20% B for 1.5
min, and returned to initial conditions in one step. The HPLC
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Figure 1. (a) Schematic model of the absorption and NiAc disposition. Ag is the amount of NiAc in the gut; Cp and Ct are the plasma
and peripheral concentrations, respectively. Dosep denotes the oral dosing, Synt the endogenous synthesis of NiAc, and Inf the intravenous
infusion. NiAc disposition in normal rats is described by a two compartment model with two nonlinear elimination terms. Translocation from
the gastrointestinal tract is described by a linear and a nonlinear process. (b) Schematic model of NiAc disposition for obese Zucker rats. NiAc
disposition is described in obese rats by a one compartment model with a nonlinear elimination term.
system was connected to a Sciex API 4000 quadrupole mass
spectrometer with a positive electrospray ionization interface
(Applied Biosystems, Ontario, Canada) and the mass transi-
tion was 124.0 > 80.2. Data acquisition and data evaluation
were performed using Analyst 1.4.1 (Applied Biosystems). The
method showed linearity over a concentration range of 0.001–
28 :mol L−1. The lower limit of quantification was 1 nmol L−1
applying a sample volume of 50 :L plasma. Plasma NEFA was
analyzed using an enzymatic colorimetricmethod (WakoChem-
icals GmbH, Neuss, Germany) adapted to a 96-well format.5
Pharmacokinetic Model of NiAc Disposition
Pharmacokinetic models of different complexity have previ-
ously been evaluated3–5 for both normal and obese animals.
As this study primarily focus on quantifying differences in PD
across different animal populations, the PKmodel used to drive
the PD model was adapted without alterations from a previous
study.3,15 A schematic picture of the chosen models is shown in
Figure 1.
The PK model handles the different administration routes,
such as constant infusion, stepwise infusion schemes, and oral
dosing. For the oral dosing, disappearance of NiAc from the gas-
trointestinal tract was modeled by one linear and one capacity-
limited elimination process operating in parallel according to
dAg
dt
= −A1 − A2 = −kaAg − Vmax,gAgKm,g + Ag , (1)
where Ag is the amount of drug in the gut. The rates A1 and
A2 correspond to the linear and the nonlinear translocation of
the drug from the gut, respectively. The parameter ka is a first
order absorption constant, Vmax,g is the maximum absorption
rate, and Km,g corresponds to the amount of drug in the gut
for which the rate of the capacity-limited elimination process is
50% of Vmax,g. The dispositionmodel of NiAc for normal animals
is described by
Vc
dCp
dt
= Inf + A1 + A2 + Synt− Vmax1Km1 + CpCp
− Vmax2
Km2 + CpCp − CldCp + CldCt (2)
Vt
dCt
dt
= CldCp − CldCt, (3)
where Cp and Ct denote the NiAc concentration in the cen-
tral and peripheral compartments with volumes Vc and Vt, Inf
the drug infusion rate of NiAc, Synt the endogenous synthesis
rate, Vmax1 and Km1 the maximal rate and Michaelis–Menten
parameter of the high affinity process, Vmax2 and Km2 the max-
imal rate and Michaelis–Menten parameter of the low affinity
process, and Cld the intercompartmental clearance. The en-
dogenous concentration of NiAc was estimated according to the
solution of the Eqs. 2 and 3 at steady state. The disposition of
NiAc in obese Zucker rats was modeled by a one compartment
model with endogenous synthesis, Synt, of NiAc and capacity-
limited elimination (see Fig. 1)
Vc
dCp
dt
= Inf + Synt− Vmax1
Km1 + CpCp (4)
where Cp denotes the NiAc concentration in the central com-
partment, Vc the central volume of distribution, Inf the drug
infusion rate, Synt the endogenous synthesis rate. The parame-
ters Vmax1 and Km1 denote the maximal rate and the Michaelis–
Menten parameter, respectively. In Table 1, the previously esti-
mated model parameter values are shown for both normal and
obese rats.
Feedback Model of NEFA
To describe the indirect response relationship between NiAc
and NEFA plasma concentrations, the feedback model in
Figure 2 is used. NiAc affects NEFA plasma concentrations
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Table 1. Fixed Effects Population Pharmacokinetic Parameter Estimates and Interindividual Variability (IIV) with Corresponding Relative
Standard Errors (RSE%)
Obese Zucker Rats Normal Sprague–Dawley Rats
Parameter Definitions Estimate (RSE%) IIV (RSE%) Estimate (RSE%) IIV (RSE%)
Vmax1 (:mol min−1 kg−1) Max. velocity, pathway 1 1.59 (13.9) 21.4 (234) 0.0871 (22.8) 92.7 (27.5)
Km1(:mol L−1) MMa constant, pathway 1 18.9 (21.5) – 0.235 (29.2) –
Vmax2 (:mol min−1 kg−1) Max. velocity, pathway 2 – – 7.09 (39.6) 29.1 (43.6)
Km2 (:mol L−1) MMa constant, pathway 2 – – 74.5 (43.4) –
Vc (L kg−1) Central volume 0.323 (12.4) – 0.393 (5.29) –
Vt (L kg−1) Peripheral volume – – 0.172 (35.2) –
Cld (L min−1 kg−1) Intercompartmental distr. – – 0.000852 (27.8) –
Synt (:mol min−1 kg−1) Endogenous synthesis rate 0.00280 (10.1) 95.3 (115) 0.00355 (23.3) 109 (34.7)
ka (min−1) First order absorption rate – – 0.00477 (33.5) 10.8 (93.1)
Vmax,g (:mol min−1kg−1) Maximum absorption rate – – 2.96 (21.3) 10.8 (93.1)
Km,g (:mol kg−1) Amt. in gut at half Vmax,g – – 20.5 (29.6) –
F1 Residual prop. Error 40.0 (26.3) – 42.8 (5.16) –
F2 Residual add. Error – – – –
Previously published in Refs. 4,5.
aMichaelis–Menten constant.
Figure 2. Schematic feedback model of NEFA production in normal
and obese rats. The NEFA turnover is described as a feedback model
with eight moderator transit compartments. The solid and dashed lines
represent fluxes and control processes, respectively. See Table 2 for an
explanation of each model parameter.
by inhibition of hydrolysis of TG to NEFA and glycerol
in adipocytes, thereby reducing the release of NEFA into
plasma.16–18 A fraction of NEFA will remain in the circulation,
unaffected by NiAc, representing the lower physiological limit
of NEFA in plasma. This process is incorporated as a zero-order
production term, kcap, in the model. Feedback in the systemwas
modeled as amoderator distributed over a series of eight transit
compartments where the moderator in the first compartment,
M1, inhibited the formation of NEFA, which we denote by R
(i.e., the build-up of NEFA concentrations). NEFA formation is
modeled as
dR
dt
= kin 1Mp1
I(Cp)+ kcap − koutRM8, (5)
whereM1 is themoderator in compartment one,M8 themodera-
tor in compartment eight, kin the turnover rate, p the amplifica-
tion factor, I(Cp) the inhibitory drug function, kcap the formation
of NEFA in capillaries, and kout the fractional turnover rate. For
describing the inhibitory drug mechanism, the following func-
tion was used
I(Cp) = 1− Imax C
(
p
IC(50 + C(p
, (6)
where Imax, IC50, and ( are the maximum drug-induced in-
hibitory effect, plasma concentration at 50% reduction of max-
imal effect (potency), and sigmoidicity factor, respectively. The
turnover of the moderators was given by
dM1
dt
= ktol(R−M1) (7)
dM2
dt
= ktol(M1 −M2) (8)
dM8
dt
= ktol(M7 −M8), (9)
where ktol is a fractional turnover rate constant. NEFA build-up
R and moderatorMi (where i= 1, . . . , 8) at baseline and steady
state becomesMi,0 = R0 and the relation between turnover rate
kin, the baseline NEFA concentration,R0, kout, and kcap becomes
kin = (koutR20 − kcap)Rp0. (10)
This relationship can be used to eliminate a redundant param-
eter from the model, for instance by expressing kin in terms of
kout andR0. The eighthmoderator compartment,M8, stimulates
the loss of R. The dual-action of insulin on NEFA regulation is
captured by M1 and M8, where M1 describes the rapid inhibi-
tion of the hydrolysis of TG to NEFA and glycerol, and M8 the
delayed stimulation of reesterification of NEFA to TG.19–22 The
moderator was affected byR via a first-order process, ktol R, and
each transduction step used the same transit time, 1/ktol. When
NiAc inhibits the formation of R, it decreases. Consequently,
the production of moderatorM1 will decrease. Since the forma-
tion of NEFA is inversely proportional to the moderator raised
to the power of p, the formation of NEFA will thus increase.
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After a delay, the level of moderator in the final compartment,
M8, will also decrease, resulting in a smaller loss of NEFA.
Eventually, the concentrations of R and Mi (i = 1, . . . , 8) will
equilibrate.
Joint Feedback Model of NEFA for Both Normal Sprague–Dawley
Rats and Obese Zucker Rats
Pharmacodynamic parameters have previously been shown to
differ between normal and obese rats.4,5 It is therefore impor-
tant to quantify these differences as this information could be
used to scale from the normal model to the disease model in,
for instance, a compound ranking situation. In previous stud-
ies, the main differing characteristics were an increased NEFA
baseline, R0, more distinct development of tolerance during
NiAc administration and a lower rebound peak.3–5 The parame-
ter estimate that differed the most except the baseline estimate
R0 was the fractional turnover kout. However, these are func-
tionally related with kin which is a derived parameter in our
model see Eq. (10). Also, there was a noticeable difference in (,
the sigmoidicity factor.
Our suggestion is to design a covariate model to handle both
normality and disease in the NiAc/NEFA model. The parame-
ters identified to differ between the groups were replaced with
a categorical variable dependent on whether the subject be-
longed to the obese or normal group. For example, for the NEFA
baselineR0, we have themodified parameter for individual i ex-
pressed as
Rmod0 = ZiRN0 + (1− Zi)RD0 , (11)
where Zi is either 1 or 0 depending on whether the individual
belongs to the normal or obese group, respectively, and R0N
is the parameter value for the normal animals and R0D for
the diseased animals. Equivalent expressions are used for the
parameters kout and (. For every disjoint parameter between
normal Sprague–Dawley rats and the obese Zucker rats this
leads to at least one additional parameter to estimate, since
both the actual parameter and its variation may need to be
estimated. In addition, other parameters could be set to differ
between the groups. As a first attempt, we chose R0, kout, and
( to find a model that can translate between normal and obese
rats.
Initial Parameter Estimates
This procedure has been described previously.3,4,23 All initial
estimates are shown in Table 2. The parameter kin is a derived
parameter, see Eq. (10). The efficacy Imax is fixed to 1 and the
sigmoidicity, (, and amplification factor, p, are initially set to
1. The parameters R0, kout, kcap, ktol, and IC50 are all derived
manually from data. In response to a high dose of NiAc (Cp 
IC50), Eq. (5) is approximated by
dR
dt
= kcap − koutRM8. (12)
Provided kcap is initially much less than kout RR0, Eq. (12)
can be simplified to
dR
dt
= −koutRR0, (13)
Table 2. Initial Parameter Estimates for Pharmacodynamic Model
of NEFA Plasma Concentration
Parameter Definitions
Normal
Sprague–
Dawley
Rats
Obese
Zucker
Rats
R0 (mmol L−1) Baseline NEFA
concentration
0.2 0.05
kout (L mmol−1 min−1) Fractional turnover
rate
0.03 0.03
ktol (min−1) Turnover rate of
moderator
0.001 0.001
kcap (mmol L−1 min−1) Turnover rate of
moderator
1 1
p Amplification
factor
0.08 0.08
IC50 (:mol L−1) Potency 1 1
( Sigmoidicity factor 1 1
where M8 is approximated by R0 because of the delay caused
by the cascade of moderators. Thus, the initial downswing of R
on a semi-logarithmic plot gives a slope of −koutR0. The lower
physiological limit of NEFA was reached following the highest
dose of NiAc. Hence, kcap was estimated from
kcap = koutR2SS, (14)
where Rss denotes the manually approximated steady state re-
sponse. The initial estimate of ktol can be approximated from
the time course of the log-linear decline of NEFA postrebound.
The IC50 value was approximated by the concentration of NiAc
resulting in a half-maximal response following a 30 min infu-
sion.
Parameter Estimation
Parameters are estimated by optimizing the approximate pop-
ulation likelihood function resulting from the FOCE approxi-
mation, see the Supporting material. The optimization prob-
lem is solved using the gradient-based method BFGS.24 The
gradient of the objective function needed by such methods is
typically computed by finite difference approximations. How-
ever, finite difference approximations might become an unre-
liable description of the gradient due to the numerical solu-
tions of the model equations. Numerical ODE solvers using
adaptive step length are known to introduce quantification er-
rors to the objective function, making it non-smooth on small
scales.25,26 To overcome such problems, the gradient can be de-
termined by formally differentiating the objective function Eq.
26. To calculate the components of the gradient w.r.t. the pa-
rameters, one typically needs to solve the so called sensitivity
equations.27,28 These equations are obtained by differentiating
the system equations with respect to the parameters to be esti-
mated. Not only is the approach of using sensitivity equations
more accurate, it is also generally faster since a lot of likelihood
function evaluations are avoided. The estimation routine was
implemented in Mathematica 9 (Wolfram Research, 2012).
Mixed-effects modeling of the NiAc/NEFA system were pre-
viously performed separately for normal rats and obese rats
by utilizing NONMEM (Version VI level 2.1; Icon Development
Solutions, Hanover, Maryland).3,4,23 Interindividual variability
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Table 3. The Ratios Between Estimated Parameters in the Joint
and Separate Models
koutD/N 1.18
(D/N 0.138
R0D/N 1.443
was modeled as lognormally distributed parameters for all dis-
position parameters of NiAc and NEFA and the random resid-
ual variability was modeled as a function of proportional or
additive error for the PK and PD. The individual disposition
parameters of NiAc were introduced as fixed parameters in the
analysis of NEFA data.
RESULTS
Disposition Analysis of NiAc
The parameters of the PK model have previously been
estimated3 using time series data of NiAc plasma concentra-
tion. Hence, these values will be used in present analysis. The
parameter values are shown in Table 1.
Feedback Model of NEFA
Table 3 displays the resulting parameter estimates together
with the results from our previous study.4 The parameter es-
timates are similar to those previously found. However, our
method gives a more robust estimate in terms of initiation of
the estimation. Using NONMEM, it is possible to reach the
same optimum by manually restarting the estimation algo-
rithm closer and closer to this point in the parameter space
and acknowledging that the approximate population likelihood
function becomes larger. With our more accurate method for
calculating the gradient, we can start the estimation in the de-
rived initial values and still reach this set of parameter values.
This gives a less complex and subjective optimization.
The observed time profiles of NEFA plasma concentrations
for all doses and subjects, including both obese Zucker rats and
normal Sprague–Dawley rats, are shown together with the re-
sults of the population model simulations using the estimated
parameters in Figure 3. In all cases, NiAc administration de-
creased NEFA plasma concentrations. As NiAc concentration
is decreased there is a rapid return to, and above, the predose
baseline concentration of NEFA. An oscillatory behavior is ob-
served post rebound until the system has returned to baseline.
The magnitude of the overshoot increases with increasing NiAc
exposure, either in duration of administration or amount. Sim-
ulated responses of a typical individual (with random effect
parameters set to zero) are shown together with the population
variability bands calculated by the Monte Carlo method.29 The
simulated variability bands give additional information about
the variability in population dynamics. The variability bands
were constructed in the following way. First, a large number
of parameter sets were sampled according to their estimated
distributions. Then, each parameter set was used for simulat-
ing the PD model. The bands mark, at each simulated time
point, the 5% and the 95% quantile of the simulated NEFA
plasma concentrations. Note that complete bands do not corre-
spond to a model simulation with a specific parameter set, but
are a representation of all the 90% intervals at each simulated
time point. Comparing the experimental data to the variability
bands revealed that 1274 data points out of in total 1440, or
88.5%, resided within the bands.
The model also performs well at the individual level, show-
ing high consistency between experimental data andmodel pre-
dictions. This is illustrated in Figure 4, where representative
individual fits are shown for all administrations. Because of its
flexibility the model captures, the vast differences of the vari-
ous drug provocations. However, the tolerance build up for the
longer infusion experiments is not completely captured, which
might indicate a possible need for an additional mechanistic
component in the model.
Figure 5a shows the concentration–response relationship at
steady state for the separate models. It shows an upward shift
and a more shallow behavior in the concentration–response
relation for the obese animals compared to the normal ones.
The normal profile is also more s-shaped than the disease
profile which is flatter. Population variability bands, resulting
from the interindividual variability of the parameters, are dis-
played. Note that the bands do not correspond to a response–
concentration relationship for an actual individual but to the
population variability in responses at each simulated concen-
tration.
Joint Analysis and Disease Model
The joint NEFA feedbackmodel is defined in section Joint Feed-
back Model of NEFA for Both Normal Sprague–Dawley Rats
and Obese Zucker Rats. The parameter estimates for this model
are shown in Table 3. For normal rats, kout was decreased in the
joint analysis compared to the separate analysis. Conversely,
the value of the parameter kout for obese rats was increased,
becoming more similar to the value of the normal rats. The
estimated values of the sigmoidicity factor, (, and NEFA base-
lines, R0, did not differ significantly for either normal or obese
rats compared with the separate analysis. Table 3 also shows
the values of the interindividual variation (IIV), which gen-
erally increase in the joint analysis compared to the separate
analysis.
Figure 5b shows the concentration–response relationship at
steady state for the joint model. The response is similar to the
separate models but the population variability is increased,
especially for obese rats. We also note a slightly decreased slope
in the response for obese rats in the joint model.
Figure 6 shows population model fits from the separate anal-
ysis together with results from the joint analysis for a 30 min
infusion of 20 :mol kg−1. Figures 6a and 6b show the results for
normal animals in the separate and joint model, respectively.
Figures 6c and 6d show the corresponding results for obese
animals. We observe that the dynamics for the normal group
does not change extensively. However, for the obese group the
population model curve slightly changes shape when the in-
formation from the normal group is included. Additionally, the
variability in obese response in the joint model is markedly in-
creased compared with the separate analysis. In Table 4, the
ratios between the joint and separate parameter estimates are
listed.
The joint model uses categorical covariates to make a dis-
tinction between healthy and diseased subjects. However, we
may hypothesize the existence of disease conditions lying in-
between these two groups. We suggest that our joint model
can be used to describe various “degrees of disease” by letting
the variables Zi take values in the continuous range between
Tapani et al., JOURNAL OF PHARMACEUTICAL SCIENCES DOI 10.1002/jps.24077
RESEARCH ARTICLE – Pharmacokinetics, Pharmacodynamics and Drug Transport and Metabolism 7
Figure 3. Observed NEFA plasma concentration–time profiles together with population model fits of NEFA plasma concentrations–time data
for normal Sprague–Dawley rats after infusion (a–h), oral administration (i–k), for obese Zucker rats after infusion (l–m). Infusion of (a) 1 :mol
kg−1; (b) 5 :mol kg−1; (c) 20 :mol kg−1, over 30 min; (d) 5 :mol kg−1; (e) 10 :mol kg−1; (f) 51 :mol kg−1, over 300 min; (g) 5 :mol kg−1 over
30 min followed by a stepwise decrease in infusion rate every 10 min for 180 min; (h) 5 :mol kg−1 over 30 min followed by a stepwise decrease
in infusion rate every 10 min for 180 min, and another 5 :mol kg−1 infusion over 30 min. Oral dose of (i) 24 :mol kg−1, (j) 82.1 :mol kg−1,
and (k) 812 :mol kg−1. Infusion of (l) 20 :mol kg−1 over 30 min and (m) 51 :mol kg−1 over 300 min. Shaded bands show the Monte Carlo 90%
population variability bands that describe the variability of the population.
0 and 1. Based on this idea, we decided to quantify the ex-
tent and variability of the rebound effect following the termi-
nation of a 300 min infusion. The extent of rebound was de-
fined as the maximum level of NEFA reached, expressed in
percentage above the baseline. Simulations were performed
for six different levels of degree of disease, and for three dif-
ferent doses, see Figure 7. Monte Carlo simulations of 1000
sampled individuals were used for each condition. Since PK
models differed for normal and obese rats, both PK models
were solved simultaneously and the solutions were weighted
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Figure 4. Representative individual model fits together with individual data of NEFA plasma concentration–time data for normal Sprague–
Dawley rats after infusion (a–h), oral administration (i–k), for obese Zucker rats after infusion (l–m). Infusion of (a) 1 :mol kg−1; (b) 5 :mol
kg−1; (c) 20 :mol kg−1, over 30 min; (d) 5 :mol kg−1; (e) 10 :mol kg−1; (f) 51 :mol kg−1, over 300 min; (g) 5 :mol kg−1 over 30 min followed by a
stepwise decrease in infusion rate every 10 min for 180 min; (h) 5 :mol kg−1 over 30 min followed by a stepwise decrease in infusion rate every
10 min for 180 min; and another 5 :mol kg−1 infusion over 30 min. Oral dose of (i) 24 :mol kg−1, (j) 82.1 :mol kg−1, and (k) 812 :mol kg−1.
Infusion of (l) 20 :mol kg−1 over 30 min and (m) 51 :mol kg−1 over 300 min.
accordingly. For the two lowest doses, the median extent of
the rebound was highest for intermediate degrees of disease,
whereas the highest dose showed a monotonically decreas-
ing median rebound with increasing degree of disease. For all
doses, there is a clear trend of markedly decreased variability
in the extent of rebound as function of increased degrees of
disease.
Sensitivity Analysis
Sensitivity analysis is used to determine which parameters are
most important in a model.30 It can answer questions about
which parameters that affect a measurable entity the most, or
how easy it is to identify one specific parameter compared with
others. This information may be used for experimental design,
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Figure 5. Simulated steady-state plasma concentration versus predicted NEFA plasma concentration at equilibriumwith population variability
bands. These results were derived using the estimated parameters from Table 3 for obese (solid) and normal rats (dashed) estimated separately
(left) and from the joint (right) model at steady state. Red bands correspond to obese rats and blue bands to normal rats.
Figure 6. Population model fits of NEFA plasma concentration–time data for normal Sprague–Dawley rats after infusion (a and b) with 20
:mol kg−1 for 30 min and (c and d) the corresponding plots for obese Zucker rats. Panels (a and c) correspond to NEFA plasma concentrations
simulated with the parameter estimates resulting from the separate analysis and panels (b and d) to the estimates from the joint analysis,
respectively. Shaded bands show the Monte Carlo 90% population variability bands that describe the variability of the population.
including when and how to take samples. Sensitivity analysis
is performed by analyzing how a small variation of a parameter
value relates to a small variation of a response variable.
We performed this analysis for all the parameters of the PD
system with the NEFA plasma concentration as the response
variable. Figure 8 shows a panel plot of the time-dependent
sensitivities for one NiAc administration route, namely con-
stant infusion for 300 min with a dose of 51 :mol kg−1 of NiAc.
The plots are ordered in size of magnitude for the derivatives of
the response w.r.t. each parameter. The parameter ktol affects
the response the most of all the PD parameters, followed by
kcap.
DISCUSSION
Compound ranking in early drug discovery phase is often based
on limited results obtained from animal models of normal or
special populations. It is therefore important to understand
and quantify the PD differences between disease and normal-
ity. Obesity causes physiological changes that can alter how
a drug regulates turnover of the response.6–10 In particular,
NEFA turnover is altered to respond differently to NiAc in the
obese Zucker rat compared with the normal Sprague–Dawley
rat. Therefore, the amount of NiAc required to reach the desired
effect is expected to be different in normal and obese animals.
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Table 4. Population Pharmacodynamic (NEFA Response) Parameter Estimates and Interindividual Variability (IIV) with Corresponding
Relative Standard Errors (RSE%)
Joint Analysis Separate Analysis Ahlstro¨m et al.
Parameter Definitions Estimate IIV Estimate IIV Estimate IIV
Normal Sprague–Dawley Rats
R0 (mmol L−1) Baseline NEFA
conc.
0.741(4.42) 19.7(31.3) 0.739(3.50) 19.9(28.1) 0.736(4.33) 21.6(27.3)
kout (L mmol−1 min−1) Fractional turnover
rate
0.290(10.1) 71.4(11.4) 0.316(9.83) 47.4(10.7) 0.273(10.2) 42.7(11.3)
ktol (min−1) Turnover rate
moderator
0.0245(2.00) – 0.0239(1.92) – 0.0231(1.90) –
kcap (mmol L−1 min−1) NEFA form. in
plasma
0.0245(10.2) – 0.0281(9.85) – 0.0230(10.1) –
kin (mmol L−1 min−1)a Turnover rate
NEFA
0.0940 – 0.102 – 0.0844 –
p Amplification factor 1.20(4.02) – 1.15(2.61) – 1.13(2.76) –
IC50 (:mol L−1) Potency 0.0820(15.5) 129(40.1) 0.0757(14.9) 134(36.2) 0.0680(15.4) 131(34.9)
( Sigmoidicity factor 2.16(4.87) – 2.19(4.33) – 2.18(4.48) –
Imax Efficacy 1 – 1 – 1 –
F1 Residual prop. error – – – – – –
F2 Residual add. error 0.0110(2.84) – 0.0102(2.45) – 0.00913(2.63) –
Obese Zucker rats
R0 (mmol L−1) Baseline NEFA
conc.
1.07(6.34) 24.0(40.6) 1.04(6.31) 15.8(34.2) 1.06(6.52) 14.8(34.6)
kout (L mmol−1 min−1) Fractional turnover
rate
0.343(31.1) 151(72.1) 0.0683(24.0) 29.7(63.6) 0.0986(24.5) 69.5(62.9)
ktol (min−1) Turnover rate
moderator
0.0245(2.00) – 0.0697(9.87) – 0.0297(10.2) –
kcap (mmol L−1 min−1) NEFA form. in
plasma
0.0245(10.2) – 4.94 × 10−8(−) – 0(fixed) –
kin (mmol L−1 min−1)a Turnover rate
NEFA
0.399 – 0.0837 – 0.125 –
p Amplification factor 1.20(4.02) – 3.19(15.3) – 2.01(15.8) –
IC50 (:mol L−1) Potency 0.0820(15.5) 129(40.1) 0.0433(49.6) 74.7(39.6) 0.0538(56.5) 135(43.4)
( Sigmoidicity factor 0.298(9.63) – 0.563(8.99) – 0.347(9.34) –
Imax Efficacy 1 – 1 – 1 –
F1 Residual prop. error – – – – 12.0(19.9) –
F2 Residual add. error 0.0110(2.84) – 0.0111(2.56) – – –
aCalculated as a secondary parameter.
Figure 7. The effect of degree of disease on extent and variability of rebound. The extent of rebound following the termination of a 300 min
infusion was quantified as the maximum level of NEFA reached, expressed in percentage above the baseline. The population variability of this
quantity was calculated for different degrees of disease (0%, 20%, 40%, 60%, 80%, and 100%, respectively) for three different doses (5, 10, and
51 :mol kg−1, respectively). Results are presented as box and whisker plots, showing the median values, 25% and 75% quantiles, respectively,
and the minimum and maximum observations. For each dose, a trajectory is joining the medians to emphasize the changes in extent of rebound
as a function of the degree of disease.
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Figure 8. Time-dependent sensitivity analysis for a constant infusion for 300 min with a dose of 51 :mol kg−1 of NiAc in normal rats. The
response, plasma concentration of NEFA, has been differentiated with respect to each parameter of the pharmacodynamic system.
Previous studies of the differences between normal Sprague–
Dawley rats and Zucker rats that were not obese showed that
they have similar lipid and lipoprotein profiles and small differ-
ences in physiological characteristics such as insulin levels.31,32
In contrast are the obese Zucker rats, where the physiologi-
cal characteristics differed significantly to the lean Sprague–
Dawley rats, with higher insulin concentrations and NEFA
baseline was approximately 70% higher than for the lean ones.
The obese rats showed insulin resistance since blood glucose
levelswere the same as in normal rats in spite of the fact that in-
sulin concentrations were significantly higher in obese animals.
In this study, we further evaluated and quantified the difference
in PD between normal Sprague–Dawley rats and obese Zucker
rats.
Feedback Model of NEFA
Administration of NiAc led to a rapid decrease in NEFA plasma
concentrations, and previously published results show that
these concentrations have a lower physiological limit.3–5 During
longer infusions, we observe tolerance, by which the NEFA con-
centrations slowly rise with a rapid rebound above the predose
baseline when the infusion is terminated. Tolerance build-up
occurs in response to all types of NiAc administrations, but was
less evident for obese Zucker rats. These rats have developed
a resistance to insulin and their NEFA response to changes in
NiAc concentration is less sensitive than that of the normal
rats. The tolerance builds up more smoothly and the overshoot
is not as pronounced as for the normal rats. The discrepancy
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between normal and obese rats leads us to the assumption that
disease changes physiological effects on the PD. Thus, the joint
model can be an appropriate tool for translating from the nor-
mal rat model to the disease rat model when such translation
is necessary.
Our investigation of the NEFA PD showed that, the main
differences between obese and normal rats were an increased
NEFA baseline concentration, more distinct development of tol-
erance during NiAc administration and a lower rebound peak.
Parameter estimates that differed the most were the baseline
estimate R0, the turnover rate kin, and the fractional turnover
kout. These are functionally related, as indicated in Eq. (10).
The more flat and upwardly shifted relationship between NiAc
concentration and NEFA response explains the greater extent
of tolerance and lack of rebound in obese animals. Also there
is a pronounced difference in the sigmoidicity parameter, (. In
conclusion, these results are similar to previous results.4
The population variability bands introduced in our study
account for the variation in system dynamics that is due to
interindividual parameter variability. This is an important ex-
tension to previous results, which did not address variations in
dynamics and response. However, our analysis is restricted to
the assumption of uncorrelated random parameters. This as-
sumption gives a tractable optimization problem in terms of
parameter identifiability, but may lead to an overestimation of
the population variability.
Concentration–Response Relationship
Figure 5a shows the concentration–response relationship be-
tween NiAc and NEFA at steady state for normal (dashed) and
obese (solid) for the separate models. Comparing the normal
and obese responses shows, as expected, an upward shift and
a more shallow concentration–response relation for the obese
animals. The normal profile is also more s-shaped than the
disease profile which is much flatter. This profile is conclusive
in a system with (more) insulin insensitivity, as is the case
for the obese Zucker rats.4 The concentration–response curves
provide a prediction of drug effects when scaling from normal
individuals to individuals with disease. For instance, increas-
ing the NiAc concentration beyond 1 :mol/L does not change
the NEFA steady-state response in normal rats. However, for
obese rats the response continues to decrease as NiAc steady-
state concentration is further increased for another two orders
of magnitude.
Joint Analysis and Disease Model
The joint model, with three parameters differing between the
normal and the diseased groupmanages to capture the features
separate models, as shown in Figure 6. These three parame-
ters do give a compact description of the main characteristics
that differ between normal and obese rats. Firstly, inspecting
the time series data in Figure 3, it is obvious that the base-
line NEFA plasma concentration, determined by the parame-
ter R0, differs significantly between the groups. Secondly, the
nonlinearity of the concentration–response relationships is a
consequence of the sigmoidicity parameter (. The dramatically
smaller ( in diseased animals suggests an inherent resistance
of the system to changes in NiAc concentration. Finally, since
the down-swing of NEFA differs between the two groups, one
also expects the fractional turnover rate kout to differ. Com-
paring the parameter values between the two groups seen in
Table 4 as ratios gives an idea of how to quantify the magnitude
of disease by concentrating the information from the parameter
estimation into a more compact description. The results from
the joint-analysis build on the strength of the extensive data
from normal rats. The uncertainty of the IC50 value for obese
rats is reduced fourfold and we gain significant higher preci-
sion in our parameter estimates. The combination of fast NiAc
kinetics with a build-up of tolerance in the NEFA response
can lead to extensive rebound effects. This is undesirable since
NEFA levels much higher than the baseline level is a poten-
tial safety issue. It has previously been shown that the extent
of rebound is influenced by the duration of NiAc exposure and
that rebound is substantially higher in normal rats. Using the
joint model derived in this study, we have further character-
ized the rebound effect by simulating its population variability
and investigating its dependence on a hypothesized degree of
disease (Fig. 7). Interestingly, for lower doses it appears that
the rebound effect may be strongest for intermediate degrees of
disease. We additionally found that the population variability
of the rebound effect has a strong dependence on the degree
of disease, with comparatively little variability among the fully
diseased animals. Taken together, these simulation results sug-
gest that the rebound effect, and hence its impact on the dose
planning for an animal disease model, may be very sensitive to
the exact degree of disease.
In conclusion, joint models can be used as a tool when screen-
ing drugs on normal animals and then translating the results
to the disease model, giving scientists a way to quantify and
evaluate the differences between the normal subject and the
diseased subject.
New Estimation Algorithm
The parameters of the present analysis were estimated by op-
timizing the approximate population likelihood function of the
problem resulting from the FOCE method but with gradients
computed by a method that has higher precision than the finite
difference approximation of the gradient used in NONMEM.13
Because of the higher precision, we were able to provide better
estimates for the IIV of IC50 and kout, which was shown to be
significantly decreased compared with previous work. We also
note that our method, based on the sensitivity equations, can
reach the optimum from the manually derived initial estimates
without repeatedly restarting the optimization from new initial
values. Compared to NONMEM, this gives a more robust calcu-
lation of the optimal parameter set in the sense of convergence
properties since no manual supervision is needed.
Sensitivity Analysis
Some of the sensitivity profiles in Figure 8 showed similar be-
havior, for example, IC50 and kin and, ( and p. These simi-
larities indicate dependencies between parameters, which can
lead to identifiability issues in the parameter estimation. For
future models, it may be valuable to reduce or reparameter-
ize the model in order to improve identifiability. Sensitivity
analysis also shows which parameters are important at differ-
ent transient behaviors. We deduced that many of the param-
eters affect the response during the onset and the end of NiAc
administration, and during the rebound phase. For instance,
the fraction turnover rate ktol is the parameter that affects
the NEFA plasma concentration response the most. Similarly,
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kin, the turnover rate of NEFA, is most important at the end of
infusion.
The analysis is carried out separately for each parameter
keeping all but one parameter fixed. The ultimate goal would
be to also include expected or estimated covariation of parame-
ters in the sensitivity analysis to better characterize the actual
system response to observed variation.
Another use of sensitivity analysis is to guide the design of
experiments. The sensitivity profiles in Figure 8 show the im-
portance of dense sampling at the start and end of infusion,
when the response is most rapid. It is common to have fast
transients in the beginning of an administration, and in some
studies it is known to be valuable to sample often at the start.
However, our analysis shows that the parameter estimates are
substantially affected by information collected post infusion.
We suggest a design, if possible for ethical reasons, with more
samples taken at the end of the experiment for increased pre-
cision of the parameter estimates.
Recommendations and Value for Drug Discovery
Disease may alter both the PK and the PD of a drug, resulting
in an altered concentration–response relationship, resulting in
an altered concentration–response relationship. Therefore, a
quantitative approach in modeling is important even in the
early stages of drug discovery.
Administration of NiAc leads to a tolerance build-up and to
extensive rebound in normal Sprague Dawley rats, but not in
obese Zucker rats.4,5 The high rebound can become a safety
issue. Therefore, the population variability bands that we ob-
tained provide important knowledge about the variation in in-
dividual response.
CONCLUSIONS
In conclusion, our study shows that both the separate and the
joint model capture the PD characteristics successfully. The
joint model describes how normal and obese rats differs with
only three separate parameters, thereby yielding important in-
formation for predicting outcomes in diseased subjects based on
data from normal ones. Another important conclusion is that
the planning of experiments and dose scheduling cannot rely
on pilot studies on normal animals alone. The obese rats have
a much less pronounced concentration–response relationship
and need much higher doses to exhibit desired response. Build-
ing joint normal-disease models with scaling parameter(s) to
characterize the “degree of disease” can be a very useful tool
when designing informative experiments on disease animals.
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